KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Equity Average (2016 - 2025)

Gilead Sciences (GILD) has disclosed Equity Average for 17 consecutive years, with $19.3 billion as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Equity Average rose 8.46% year-over-year to $19.3 billion, compared with a TTM value of $19.3 billion through Jun 2025, up 8.46%, and an annual FY2024 reading of $21.0 billion, down 4.47% over the prior year.
  • Equity Average was $19.3 billion for Q2 2025 at Gilead Sciences, up from $19.2 billion in the prior quarter.
  • Across five years, Equity Average topped out at $22.5 billion in Q4 2023 and bottomed at $17.8 billion in Q2 2024.
  • Average Equity Average over 5 years is $20.0 billion, with a median of $20.1 billion recorded in 2022.
  • The sharpest move saw Equity Average decreased 17.05% in 2021, then increased 10.2% in 2022.
  • Year by year, Equity Average stood at $19.3 billion in 2021, then increased by 9.29% to $21.1 billion in 2022, then increased by 6.45% to $22.5 billion in 2023, then decreased by 16.35% to $18.8 billion in 2024, then grew by 2.74% to $19.3 billion in 2025.
  • Business Quant data shows Equity Average for GILD at $19.3 billion in Q2 2025, $19.2 billion in Q1 2025, and $18.8 billion in Q4 2024.